Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
CONTEXT: GnRH agonists markedly increase fat mass in men with prostate cancer, but little is known about the effects of treatment on insulin sensitivity. OBJECTIVE: The objective of the study was to assess the effects of short-term GnRH agonist treatment on insulin sensitivity. DESIGN: This was a prospective 12-wk study. SETTING: The study was conducted at a general clinical research center. PATIENTS OR OTHER PARTICIPANTS: We studied 25 men with locally advanced or recurrent prostate cancer, no radiographic evidence of metastases, no history of diabetes mellitus, and no evidence of diabetes mellitus at baseline visit. INTERVENTION: Leuprolide depot and bicalutamide were used in the study. MAIN OUTCOME MEASURES: Oral glucose tolerance tests and body composition assessment by dual-energy x-ray absorptiometry were performed at baseline and wk 12. The primary study outcome was change in insulin sensitivity index. RESULTS: Mean (+/- se) percentage fat body mass increased by 4.3 +/- 1.3% from baseline to wk 12 (P = 0.002). Insulin sensitivity index decreased by 12.9 +/- 7.6% (P = 0.02). Insulin sensitivity by homeostatic model assessment decreased by 12.8 +/- 5.9% (P = 0.02). Fasting plasma insulin levels increased by 25.9 +/- 9.3% (P = 0.04). Mean glycosylated hemoglobin also increased significantly (P < 0.001). CONCLUSIONS: Short-term treatment with leuprolide and bicalutamide significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer. These observations suggest that GnRH agonists may increase the risk of diabetes mellitus and cardiovascular disease in older men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 4×
“The whole-body ISI was calculated from fasting plasma insulinandglucoseconcentrationsandmeanplasmainsulinandglucose concentrations during the OGTT, with ISI 10,000/square root of (fasting plasma glucose fasting plasma insulin) (mean OGTT glucose mean OGTT insulin) ( 18 ).”
BackgroundMethodResultInfluentialDeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535 · cited 1×
“The observed increase in HDL cholesterol levels contrasts to the low levels of HDL cholesterol associated with the classic metabolic syndrome (14, 15 ).”
BackgroundPrevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699 · cited 1×
“Insulin resistance is a common metabolic abnormality that underlies type 2 diabetes mellitus (11) and is an independentriskfactorforcardiovasculardisease( 12 ,13).Insulin resistance is also linked to a variety of abnormalities associated with cardiovascular disease risk including obesity, hypertension, elevated trigly…”
BackgroundAndrogen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083 · cited 1×
“nRH AGONISTS ARE the cornerstone of treatment for metastatic prostate cancer and a routine part of management for many men with local and local-regional disease ( 1 ).”
BackgroundFerrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1992) · Medical Science Symposia Series · doi:10.1007/978-94-011-2700-4_10 · Cited by 865
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 3×
“Consistent with earlier reports ( 5 , 8, 22), we observed that”
BackgroundMethodResultSelf-citation
Cited by
Items 401–496 of 496
Bassey, I. E., Usoro, C., & Esiere, K.-U. S. (2017) · Journal of Neoplasm · doi:10.21767/2576-3903.100019 · Cited by 2
Androgen Deprivation Therapy for Prostate Cancer: Effects on Body Composition and Metabolic Health
Huang, G. T.-W., & Basaria, S. S. (2017) · Energy balance and cancer · doi:10.1007/978-3-319-64940-5_7 · Cited by 2
Introduction: Testosterone and the metabolic syndrome
Gooren, L. J., Meryn, S., & Shabsigh, R. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.03.008 · Cited by 2
“Induction of androgen deficiency in healthy men by administration of an LHRH agonist leads to an increase of fat mass [32,33].”
Male hypogonadism with its systemic complications
Niedobylski, S., Laszczak, K., Warchoł, K., Marczak, A., Dobosz, M., Lewicki, M., & Obel, E. (2020) · Journal of Education Health and Sport · doi:10.12775/jehs.2020.10.09.020 · Cited by 1
Zhang, X., Shen, H., Xu, Q., Tu, C., Peng, Y., Liu, T., Qiu, X., & Zhang, J. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112371 · Cited by 1
Management of Newly Diagnosed Metastatic Disease
Cowey, C. L., & Hutson, T. E. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-259-9_22 · Cited by 1
Testosterone Deficiency Linked to Lower Urinary Tract Symptoms
Chul, S. H. (2012) · InTech eBooks · doi:10.5772/25618 · Cited by 1
“GnRH agonist-treated men with prostate cancer also showed significantly decreased insulin sensitivity (Smith et al., 2006).”
BackgroundÁlvarez, A. Á., Falcón, M., Suárez, R. M. G., Amador, P., Calzado, M. C. A., Alonso, E. D., Puertas, A. C., Leyva, S. S., & Acosta, J. R. (2015) · Revista cubana de endocrinología · Cited by 1
Syndecan as a Messenger to Link Diabetes and Cancer
Kim, S., & Raman, O. S. (2011) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2011.19.3.267 · Cited by 1
“Also increasing evidence exists now that castration therapies used in prostate cancer may lead to hyperinsulinemia and raises concern for potential recurrence risk (Smith et al., 2006).”
BackgroundAndrogens, visceral obesity and the risks for cardiovascular disease and diabetes mellitus
Gooren, L. J. (2007) · The Journal of Men s Health and Gender · doi:10.1016/j.jmhg.2007.02.001 · Cited by 1
“The fact that androgen deprivation of men with prostate cancer induces a worsening of elements of the metabolic syndrome reveals a role for testosterone in its etiology [25,26].”
Recent perspectives on the age-related decline of testosterone
Gooren, L. J. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2007.12.003 · Cited by 2
“…it has also been documented that low testosterone induces the metabolic syndrome [14,26], as dramatically demonstrated by findings in men with prostate cancer who undergo andro-This article is made possible thanks to an educational grant from Bayer Schering Pharma AG gen ablation therapy [27–29].”
Can the administration of testosterone to men with late-onset hypogonadism be discontinued?
Gooren, L. J. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.09.005 · Cited by 1
“…clear that disease and, in particular, features of the metabolic syndrome, suppress circulating T levels, it has also been documented that low T induces the metabolic syndrome [6,31,32], dramatically demonstrated by findings in men with prostate cancer who undergo androgen ablation therapy [33–35].”
Functional and metabolic complications of androgen deprivation therapy
Herrera-Caceres, J. O. (2014) · World Journal of Clinical Urology · doi:10.5410/wjcu.v3.i3.227 · Cited by 2
Donca, V., Macarie, A. E., Paşca, L., Buzdugan, E., Bodolea, C., Rădulescu, D., Crişan, S., Stoicescu, L., Neacşu, B., & Donca, S. (2012) · Cited by 1
Mosca, A., Volpe, A., Beldì, D., Bozzola, C., Palma, R., Rubinelli, S., Pagano, L., D’Avanzo, F., Stratica, F., Alabiso, O., et al. (2016) · Acta Medica International · doi:10.5530/ami.2016.2.31 · Cited by 1
Prostate Cancer and the Metabolic Syndrome
Langley, S. E. M., & Nobes, J. P. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_8 · Cited by 1
Systemic complications in the hormonal treatment of prostate and breast cancer
Jagielska, B., Poniatowska, G., Tałasiewicz, K., Demkow, T., & Wiechno, P. (2017) · Nowotwory Journal of Oncology · doi:10.5603/njo.2017.0034 · Cited by 1
Metabolic Health for Patients with Prostate Cancer During Androgen Deprivation Therapy
Mitsuzuka, K., & Arai, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-7013-6_17 · Cited by 1
Side Effects of Medical Cancer Therapy in Genitourinary Malignancies
TOMBAL, B. F., Remacle, C., & Vubu, M. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_6 · Cited by 2
Androgen Deprivation Therapy for Prostate Cancer
(2017) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681083551117080005 · Cited by 1
TOMBAL, B. F. (2012) · Springer eBooks · doi:10.1007/978-0-85729-787-7_6 · Cited by 1
Hormone Treatment of Prostate Cancer:
Labban, M., Alkassis, M., Alkhatib, K. Y., Briggs, L. G., Cole, A. P., Kibel, A. S., & Trinh, Q. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2022.01.001 · Cited by 1
Sönmez, H. K., Sönmez, G., Doğan, S., Horozoğlu, F., Demirtaş, A., & Evereklioğlu, C. (2022) · Ophthalmic Research · doi:10.1159/000527387 · Cited by 1
“In the remaining two studies, no significant BMI increase was observed in one study, and a mean decrease of 0.39% was observed in the other study [36, 37].”
ResultInfluentialExercise as medicine : reversing treatment toxicities in prostate cancer patients
Wall, B. A. (2013) · Research Online (Edith Cowan University) · Cited by 1
State of the Art Reviews : Male Menopause: Fact or Fiction?
Wald, M., Miner, M. M., & Seftel, A. D. (2008) · American Journal of Lifestyle Medicine · doi:10.1177/1559827607311513 · Cited by 1
The Motion: Hormonal Blockade Should be Limited Due to Significant Adverse Effects
BOCCON-GIBOD, L., & TOMBAL, B. F. (2008) · European Urology · doi:10.1016/j.eururo.2008.10.006 · Cited by 1
Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?
Corsello, S. M., & Kantoff, P. W. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1015 · Cited by 1
Winkfield, K. M., & Albert, M. A. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0110-z · Cited by 1
“ADT may also lead to the development of impaired glucose tolerance or type 2 diabetes [18, 19 ].”
BackgroundWalker, L. M. (2013) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/24988 · Cited by 1
Aggarwal, R. R., Alumkal, J. J., Szmulewitz, R. Z., Higano, C. S., Bryce, A. H., Yu, M. K., de Boer, C., Choque-Gonzales, G., & Small, E. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps5084 · Cited by 1
Smith, M. R. (2008) · Current Prostate Reports · doi:10.1007/s11918-008-0023-1 · Cited by 1
Self-citationSena, L. A., Wang, H., & Denmeade, S. R. (2023) · The Prostate · doi:10.1002/pros.24582 · Cited by 1
The interrelationship of sex steroid levels, body composition and bone characteristics in men
Lapauw, B. (2009) · Ghent University Academic Bibliography (Ghent University)
The role of insulin and IGF2 signalling on metabolic pathways in prostate cancer progression
Lubik, A. A. (2011) · Faculty of Science and Technology; Institute of Health and Biomedical Innovation · Cited by 1
Strawbridge, R. J. (2008) · Figshare
Diagnosis and Management of Metastatic Prostate Cancer
TOMBAL, B. F., & Lecouvet, F. E. (2014) · Wiley eBooks · doi:10.1002/9781118347379.ch13 · Cited by 1
Hong, E. Y., Lee, S. W., Kang, J. G., Kim, C. S., Ihm, S. H., Yoo, H. J., & Lee, S. J. (2010) · The Korean Journal of Internal Medicine
Hormonal Therapy for Prostate Cancer in Men With Heart Disease
Agarwal, N. (2010) · JAMA · doi:10.1001/jama.2009.1931
Helical Tomotherapy in Elderly Prostate Cancer Patients
Ki, Y. K., Nam, J. H., Kim, W., Park, D., Kim, D. H., Lee, J. H., Jeon, H. S., & Kim, D. W. (2013) · Journal of the Korean Geriatrics Society · doi:10.4235/jkgs.2013.17.2.79
Le traitement hormonal du cancer de la prostate chez le patient âgé
Mongiat-Artus, P., Peyromaure, M., Richaud, P. M., Beuzeboc, P., Bastide, C., Cornud, F., Gaschignard, N., Molinié, V., Rozet, F., Staerman, F., et al. (2009) · The French Journal of Urology · doi:10.1016/s1166-7087(09)73363-9
Side Effects and Complications of Androgen Deprivation in Prostate Cancer Patients
Fernandez‐Castro, G. (2010) · The Open Prostate Cancer Journal · doi:10.2174/1876822901003010029
Patient Quality of Life Safeguarding: The Primary Aim in Nonmetastatic Prostate Cancer Patients
Cai, T., & Bartoletti, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3125
Effects of Androgen on the Cardiovascular System in the Aging Male
Kim, J. W., Kim, J. J., & Moon, D. G. (2011) · Korean Journal of Andrology · doi:10.5534/kja.2011.29.1.10
Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer
Nambudiri, V. E., & Keating, N. L. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.35
Lebrun, C. E. I. (2008) · EUR Research Repository (Erasmus University Rotterdam)
Lin, J., Deng, A., Hoffman-Censits, J. H., Gibney, G. T., Hyslop, T., Miller, B., Kilpatrick, D. L., Jabbour, S. A., & Kelly, W. K. (2015) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2015.11.003
Pitfalls of Androgen Deprivation Therapy
Morgans, A. K., & Smith, M. R. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-259-9_23 · Cited by 1
Self-citationLate-Onset Hypogonadism in Male Patients Over 60 Years of Age with Metabolic Syndrome
Kara, E., Çelik, Ö., Kadıoğlu, A., & Kadıoğlu, P. (2022) · Endocrinology research and practice. · doi:10.4274/tjem.2104
“Several studies have demonstrated that low testosterone levels are associated with insulin resistance and high testosterone concentrations are connected with insulin sensitivity (8-10).”
BackgroundAndrès, E., Eschwège, P., Lang, H., Peiffert, D., Thiéry, A., & Kleinclauss, F. (2012)
Tratamiento del cáncer de próstata
González, A. B. (2010)
Implication de "Liver X Receptors" dans la physiopathologie des gonades
Maqdasy, S. (2016) · theses.fr (ABES) · doi:10.70675/16b8299ez16c1z4c04zb4fbzfdd268ae88bb
“On the other side, altered testicular functions may increase the risk of metabolic syndrome (Kupelian et al., 2006; Smith et al., 2006).”
BackgroundRadiation with Hormonal Therapy
Baker, B. R., Mohiuddin, J. J., & Chen, R. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00043-8
Metabolic Complications of Androgen Deprivation Therapy for the Treatment of Prostate Cancer
Taxel, H. A. P. (2015) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.1000205
“001), and one of the 25 subjects met criteria for diabetes mellitus at the week 12 OGTT [29].”
BackgroundMethodInfluentialA Case of Diabetic Chorea Caused by Hyperglycemia during Anti-Androgen Therapy
Miura, T., HONMA, R., & Iida, T. (2016) · JOURNAL OF THE JAPANESE ASSOCIATION OF RURAL MEDICINE · doi:10.2185/jjrm.65.254
Mayer, M. (2016) · TSpace (University of Toronto)
Yıldızhan, M., Dündar, M., & Ertek, M. Ş. (2015) · Bulletin of Urooncology · doi:10.4274/uob.315
The Role of Hormonal Treatment in Prostate Cancer
Hürmüz, P., Akyol, F. H., Gültekin, M., Yazıcı, G., Sarı, S. Y., & Özyiğit, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-56114-1_20
Wallis, C. J. D. (2017) · TSpace (University of Toronto)
Donner, D. G. (2015) · Griffith Research Online · doi:10.13140/rg.2.1.1191.1761 · Cited by 1
Isbarn, H., BOCCON-GIBOD, L., Carroll, P. R., Montorsi, F., Schulman, C., Smith, M. R., Sternberg, C. N., & Studer, U. E. (2009)
Self-citationMuscle, fat and performance during androgen deprivation for prostate cancerPreprint
Owen, P. J. (2018) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/xthkv
The Patient Journey in Prostate Cancer: Key Points for Nurses
Remacle, C. (2019) · Principles of specialty nursing · doi:10.1007/978-3-319-76457-3_13
The Rag1-/- Mouse: Establishing Links between Obesity and Prostate Cancer
Maugham, M. (2019) · Queensland University of Technology · doi:10.5204/thesis.eprints.126971
Adverse Effects of Androgen Deprivation in Elderly Men with Prostate Cancer
Zarzour, A., Shevach, J. W., & Morgans, A. K. (2019) · Current Geriatrics Reports · doi:10.1007/s13670-019-00303-8
Exploring the protective effect of silymarin against flutamide-induced hepatotoxicity in male rats
(2016) · Research opinions in animal & veterinary sciences · doi:10.20490/roavs/16-040
“Such alterations in lipid profile following treatment with FLU are in agreement with several published studies (Smith et al., 2006; Ray et al., 2010; Lateef et al., 2012).”
ResultHerse, M. N. (2020) · NVA (Nasjonalt vitenarkiv)
Lam, T., Cheema, B. S., Hayden, A. J., Lord, S. R., Gurney, H., Gounden, S., Reddy, N., Shahidipour, H., Read, S. A., Stone, G., et al. (2019) · doi:10.21203/rs.2.19495/v1
Ki, Y., Nam, J., Kim, W., Park, D., Kim, D., Lee, J. H., Jeon, H., & Kim, D. W. (2013)
고순흠 (2008) · Seoul National University Open Repository (Seoul National University)
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3281de7489
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282c3a898
Ferreira, A. R., Abrunhosa-Branquinho, A. N., Vendrell, I., Quintela, A., Pina, F., & Ribeiro, L. (2015) · Springer eBooks · doi:10.1007/978-3-319-21683-6_22
Pais, H. L., Ulrich, J., & Ribeiro, L. (2019) · Springer eBooks · doi:10.1007/978-3-030-16245-0_26
Michaelson, M. D., & Smith, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3893
Self-citationSystemic Onco-Sphere: Host Metabolic System and Cancer
Saw, P. E., & Song, E. (2023) · Springer eBooks · doi:10.1007/978-981-99-1183-7_24
Exercise training in prostate cancer patients on androgen deprivation therapy
Houben, L. H. P. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240111lh
Medical Treatment of Paraphilic Sex Offenders
Cocchetti, C., & Fisher, A. D. (2023) · Trends in andrology and sexual medicine · doi:10.1007/978-3-031-47892-5_22
Haque, A. (2025) · Queensland University of Technology · doi:10.5204/thesis.eprints.256583 · Cited by 2
Kemp, B. R., Durukan, E., Skaarup, K. G., Østergren, P. B., Sønksen, J., & Fode, M. M. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04923-2
“However, evidence suggests that metabolic alterations associated with ADT manifest as early as 3 to 6 months [23, 49].”
Hanson, E. D. (2011) · University Libraries (University of Maryland)
McNaught, E., Reale, S., Bourke, L., Brown, J. E., Collinson, M., Day, F., Hewison, J., Farrin, A. J., Ibeggazene, S., Innes, A. Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25596471
Shanthaveerappa Rudrappa, S. (2021) · Nottingham ePrints (University of Nottingham) · Cited by 2
Radical prostatectomy and work : men's perspectives
Ko, Y. H. (2018) · cIRcle (University of British Columbia)
Nian, Q., Chang, L.-W., Yang, H., Li, J. T., Hung, S.-C., & Chen, I. (2026) · Cardio-Oncology · doi:10.1186/s40959-026-00445-7
“These metabolic changes could potentially lead to increased risk of cardiovascular disease [27, 28].”
Čeponis, J., Wang, C., Swerdloff, R., & Liu, P. Y. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_11-2 · Cited by 1
Radiotherapy Plus Hormonal Therapy
Holmes, J. A., & Chen, R. C. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_71
Side effects of androgen deprivation in prostate cancer and their correction: Systematic review
Savin, L. T., Balashova, K. D., Baitman, T. P., BORUKAEV, A. Y., Ахмадеев, З. Р., Savina, A. A., Monakov, D. M., Gritskevich, Е. Y., Измайлов, А. А., & Грицкевич, А. А. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-151
The relationship between prostate cancer and metabolic syndrome: A bibliometric analysis (2021–2023)
Wang, F., Wu, J., Wang, W., Hu, M., & Xi, Q. (2026) · Medicine · doi:10.1097/md.0000000000049716
“[23] Previous research has confirmed the biological mechanisms linking MetS and PCa, although the specific mechanisms are not yet fully understood, and epidemiological studies have been contradictory.”
Obi, D. J., Ehiedu, C. G., Abdus-Salam, A. A., Ntekim, A., Takure, A., Nwanji, I. D., Farinre, O., & Adenipekun, A. (2025) · Nigerian Journal of Oncology · doi:10.67579/njo.2025.z2hnreiu
Discordant molecular biomarkers in unfavorable intermediate‐risk localized prostate cancer
Rooney, M. K., Patel, K. R., Shah, S. J., Gregg, J. R., Frank, S. J., Hoffman, K. E., Park, R. J.-H., Hassanzadeh, C., Choi, S., McGuire, S., et al. (2026) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70105
The role of insulin in advanced prostate cancer
McKenzie, I. R. (2011)
Toxicity of Androgen Deprivation Therapy in Hormone-Sensitive Prostate Cancer
Akhtar, N. H., Diamond, E., Eiseler, N. T., & Tagawa, S. T. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_75
Metadata
- Authors
- Smith, M. R., Lee, H., & Nathan, D. M.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Smith, Matthew R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-04
- Volume
- 91
- Issue
- 4
- Pages
- 1305-1308
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2129509910
- Cited by
- 493
- References
- 25
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 14 · 2023: 12 · 2022: 13 · 2021: 9 · 2020: 14 · 2019: 15 · 2018: 20 · 2017: 25 · 2016: 24 · 2015: 26 · 2014: 26 · 2013: 35 · 2012: 46
- FWCI
- 32.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- Massachusetts General Hospital
- National Institutes of Health
- National Cancer Institute (P50 CA 90381, P50CA090381)
- National Center for Research Resources (M01RR001066, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- insulin sensitivity, prostate cancer, combined androgen blockade, GnRH agonist, leuprolide, bicalutamide, fat mass, insulin resistance, diabetes risk, cardiovascular risk, fasting insulin, HbA1c
- MeSH terms
- Adipose Tissue, Adult, Androgen Antagonists, Anthropometry, Blood Glucose, Body Composition, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Gonadotropin-Releasing Hormone, Lipids, Male, Prospective Studies, Prostatic Neoplasms, Testosterone, Biomarkers, Absorptiometry, Photon, Treatment Outcome, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.